I'm assuming this all comes under the broad $50m license agreement (assuming GNBT/NGIO is still working on that deal) and China partners would fund that research and development ... I wonder since China agreement seems to cover sales within China ... If the partners in China develop a Swine Flu vaccine and it is sold outside China how does that work if they do all the work and get China approval vs. GNBT/NGIO doing all the work and getting US approval?
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links